Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Neoplasms of the CNS

Free Subscription 16.03.2026 4 AJNR Am J Neuroradiol 4 Childs Nerv Syst 3 Clin Cancer Res 2 Clin Neuropathol 1 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 1 J Natl Cancer Inst 1 J Neurol 17 J Neurooncol 2 J Neuropathol Exp Neurol 4 J Neurosurg 1 Nat Rev Neurol 10 Neuro Oncol 1 Neuroradiology 1 Neurosurgery 2 Pediatr Neurosurg 1 PLoS Biol 1 PLoS One 2 Radiol Imaging Cancer 1 Radiologia (Engl Ed)

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJNR Am J Neuroradiol

1. YAHAV DOVRAT A, Namdar K, Wagner MW, Sheng M, et al
   Multiclass Radiomics-Based Prediction of BRAF Mutation Status in Pediatric Low-Grade Gliomas Using Multisequence MRI.
   AJNR Am J Neuroradiol. 2026 Mar 12:ajnr.A9296. doi: 10.3174/ajnr.A9296.
   PubMed         Abstract available
   
   
2. BENOMAR A, Ghumman SS, Ouahdi Y, Ghozy S, et al
   Volumetric Postcontrast T1 Turbo Spin-Echo versus Gradient-Recalled Echo MR sequences for Detecting Brain Metastases: a Systematic Review and Meta-analysis.
   AJNR Am J Neuroradiol. 2026 Mar 12:ajnr.A9294. doi: 10.3174/ajnr.A9294.
   PubMed         Abstract available
   
   
3. RAMEH V, Aker L, Vajapeyam S, Ziaei A, et al
   An Emerging Pediatric CNS Tumor: Imaging Evaluation of H3K27M and BRAF V600E Comutated Midline Tumors.
   AJNR Am J Neuroradiol. 2026;47:809-815.
   PubMed         Abstract available
   
   
4. WANG E, Darbandi A, Tu L, Ballester LY, et al
   Brain CT for Diagnosis of Intracranial Disease in Ambulatory Patients with Cancer: Assessment of the Diagnostic Value of Scanning without Contrast prior to with Contrast.
   AJNR Am J Neuroradiol. 2026;47:694-698.
   PubMed         Abstract available
   
   

   
   Childs Nerv Syst

5. VITULLI F, Lorenzetti M, Vasilica AM, Reisz Z, et al
   The Endoscopic ExtraForaminal TransChoroid (EFTC) Approach in the Management of Pineal Tumors: Gross Total Resection through a Single Burr Hole.
   Childs Nerv Syst. 2026;42:106.
   PubMed         Abstract available
   
   
6. ZHU R, Hu B, Zhai H, Hu C, et al
   Cerebrum functional network alterations following posterior fossa surgery in Children.
   Childs Nerv Syst. 2026;42:99.
   PubMed         Abstract available
   
   
7. NAHAL A, Elgamal EA, Al Abed A, Alakkad A, et al
   Intradural spinal bizarre parosteal osteochondromatous proliferation (BPOP): case report and review of the literature.
   Childs Nerv Syst. 2026;42:94.
   PubMed         Abstract available
   
   
8. FORMENTIN C, Matias LG, de Souza Rodrigues Dos Santos L, Miranda CEV, et al
   Hydrocephalus in pediatric posterior fossa tumors: predictors and outcomes from a single center in Latin America.
   Childs Nerv Syst. 2026;42:92.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

9. FUKUMURA K, Jiang P, Yeboa DN, Singareeka Raghavendra A, et al
   Ionizing radiation enhances prognostically significant cellular immunity programs in the brain metastasis microenvironment.
   Clin Cancer Res. 2026 Mar 12. doi: 10.1158/1078-0432.CCR-25-3525.
   PubMed         Abstract available
   
   
10. CROWELL C, Mankuzhy NP, Bennett J, Bandopadhayay P, et al
    Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-mutant: An International Multi-Institutional Study.
    Clin Cancer Res. 2026 Mar 9. doi: 10.1158/1078-0432.CCR-25-3764.
    PubMed         Abstract available
    
    
11. RICCI AD, Rizzo A
    Unlocking New Possibilities: Dual Immune Blockade in Brain Metastases from Rare Tumors.
    Clin Cancer Res. 2026 Mar 9. doi: 10.1158/1078-0432.CCR-25-4816.
    PubMed         Abstract available
    
    

    
    Clin Neuropathol

12. DAS S, Charan BD, Ahlawat S, Gupta RK, et al
    Posterior fossa ependymoma harboring H3K27M mutation: A rare case report with clinical follow-up and diagnostic challenges.
    Clin Neuropathol. 2026;45:10-16.
    PubMed         Abstract available
    
    
13. KABADAYI ED, Temena MA, Kayali FI, Beyaz H, et al
    The role of immunohistochemical CIC expression in oligodendrogliomas for recurrence risk stratification.
    Clin Neuropathol. 2026;45:2-9.
    PubMed         Abstract available
    
    

    
    Int J Cancer

14. GAO M, Zang H, Zhao W, Zhou Y, et al
    Unraveling glymphatic disruption in brain tumors: Insights from perivascular space network analysis.
    Int J Cancer. 2026 Mar 7. doi: 10.1002/ijc.70441.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

15. UNNIKRISHNAN S, Karunamuni R, Salans MA, Gudipati S, et al
    Dose-Dependent Atrophy in Bilateral Amygdalae and Nuclei After Brain Radiation Therapy and Its Association With Mood and Memory Outcomes on a Longitudinal Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2023;117:834-845.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

16. COLMAN H, Lombardi G, Wong ET, Walbert T, et al
    STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
    J Clin Oncol. 2026;44:641-652.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

17. OTTAVIANI D, Ola M, Allotta A, Maati Chaibi Y, et al
    Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.
    J Natl Cancer Inst. 2025 Oct 15:djaf295. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Neurol

18. SANDMANN ACA, Kempeneers MA, Slot KM, van den Berg R, et al
    Clinical course and patient-reported outcomes in conservatively managed spinal cavernous malformations.
    J Neurol. 2026;273:188.
    PubMed         Abstract available
    
    

    
    J Neurooncol

19. BYTNAR JA, Robins KR, Theeler BJ, Shriver CD, et al
    The relationship between asthma and glioma: a case-control study in a universal access healthcare system.
    J Neurooncol. 2026;177:38.
    PubMed         Abstract available
    
    
20. AGARWAL V
    The promise and potential of porphyrin metabolite activation using sonodynamic therapy for the treatment of glioblastoma.
    J Neurooncol. 2026;177:45.
    PubMed        
    
    
21. JUNGK C, Goepfert K, Gluszak M, Marhaba K, et al
    Prognostic relevance of resection at first recurrence in isocitrate dehydrogenase mutant lower-grade glioma: results from a retrospective, single-center, volumetric analysis.
    J Neurooncol. 2026;177:42.
    PubMed         Abstract available
    
    
22. CIOFFI G, Waite K, Baranova A, Barnholtz-Sloan J, et al
    Individualized prediction of survival after brain metastasis development in patients with breast cancer.
    J Neurooncol. 2026;177:44.
    PubMed        
    
    
23. AMPIL F, Moncrief O, Sin A, Toms J, et al
    Reduced dose single-fraction frame-based postoperative radiosurgery for large (> 10 cm(3)) brain metastases cavities: real world outcomes.
    J Neurooncol. 2026;177:43.
    PubMed        
    
    
24. GECICI NN, Stepniak A, Ozcinar KK, Habib A, et al
    Malignant transformation in IDH-mutant gliomas: clinical drivers and survival outcomes in a histologically defined cohort.
    J Neurooncol. 2026;177:37.
    PubMed        
    
    
25. PACK E, Cifarelli CP, Bhatia S, Lewis J, et al
    Glioblastoma survival in rural America: a 10-year experience from a quaternary care center.
    J Neurooncol. 2026;177:36.
    PubMed         Abstract available
    
    
26. KHATRI VM, Aboujaoude M, Karapetyan L, Tarhini AA, et al
    Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression.
    J Neurooncol. 2026;177:35.
    PubMed        
    
    
27. RONCELLI F, Snider S, Boselli D, De Domenico P, et al
    Prognostic relevance and cytokine correlates of peripheral immune subpopulations in newly diagnosed glioblastoma.
    J Neurooncol. 2026;177:34.
    PubMed        
    
    
28. ONDER T, Ates O
    Biological aging enhances prognostic stratification beyond chronological age in breast cancer brain metastases.
    J Neurooncol. 2026;177:28.
    PubMed        
    
    
29. ZHENG S, Lin L, Ren G, Lan H, et al
    Correction to: Phosphoenolpyruvate carboxykinase 2 as a prognostic biomarker: expression and clinical significance in Group 3 and Group 4 medulloblastoma.
    J Neurooncol. 2026;177:41.
    PubMed        
    
    
30. WANG Y, Xie K, Yang K, Luo A, et al
    Socioeconomic disparities in IDH-wildtype glioblastoma survival: interactions between age and household income in a SEER cohort.
    J Neurooncol. 2026;177:40.
    PubMed         Abstract available
    
    
31. ABU-ARJA MH, Stuckert A, Ghebrelul RT, Chintagumpala M, et al
    Immunotherapy approaches for the treatment of relapsed or progressive medulloblastoma.
    J Neurooncol. 2026;177:39.
    PubMed        
    
    
32. ZENG W, Jedwood C, Chung R, Cote DJ, et al
    Associations of surgical menopause and hormone replacement therapy with meningioma development.
    J Neurooncol. 2026;177:49.
    PubMed        
    
    
33. SARAF A, Ford J, Parsons M, Sherman J, et al
    Longitudinal changes of neurocognitive function and ALPS-index in patients with brain tumors receiving brain irradiation.
    J Neurooncol. 2026;177:47.
    PubMed        
    
    
34. PRINS TJ, Lai TJ, Li T, Fisher A, et al
    MGMT downregulation by CRISPR/Cas13 RNA-guided RNA targeting enhances glioma cell sensitivity to TMZ chemotherapy.
    J Neurooncol. 2026;177:48.
    PubMed        
    
    
35. LIU J, Abikenari M, Annagiri S, Ha JH, et al
    Endogenous immune recruitment in glioblastoma CAR T therapy: cytokine, myeloid, and chemokine circuitry.
    J Neurooncol. 2026;177:50.
    PubMed         Abstract available
    
    

    
    J Neuropathol Exp Neurol

36. SPYRETOS C, Pardo Ladino JM, Andersen Blomstrand H, Nyman P, et al
    Quantification of Ki-67 labeling index in pediatric brain tumor immunohistochemistry images.
    J Neuropathol Exp Neurol. 2026 Mar 10:nlaf163. doi: 10.1093.
    PubMed         Abstract available
    
    
37. EBNER BA, Ida CM, Kollmeyer TM, Jenkins RB, et al
    Association of CDKN2A/B and MTAP deletions in adult-type diffuse gliomas.
    J Neuropathol Exp Neurol. 2026 Mar 9:nlag007. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Neurosurg

38. ZOLI M, Angileri FF, Cappelletti M, Doglietto F, et al
    Endoscopic endonasal surgery for prolactin-secreting adenoma: a retrospective multicenter study by the neuroendoscopy section of the Italian Society of Neurosurgery.
    J Neurosurg. 2025 Dec 5:1-13. doi: 10.3171/2025.7.JNS242821.
    PubMed         Abstract available
    
    
39. SADIGH Y, Schouten JW, Vincent AJPE, Dirven CMF, et al
    Incidence and effect of supratentorial postoperative deep cerebral perforator territory ischemia in neurosurgical patients with intra-axial and extra-axial tumors.
    J Neurosurg. 2025 Nov 21:1-11. doi: 10.3171/2025.7.JNS242861.
    PubMed         Abstract available
    
    
40. FAN Y, Tao C, Feng M, Guo S, et al
    Multiparameter MRI-based clinical-radiomic model to differentiate prolactinoma from hyperprolactinemic nonfunctioning pituitary adenoma.
    J Neurosurg. 2025 Nov 7:1-11. doi: 10.3171/2025.6.JNS25579.
    PubMed         Abstract available
    
    
41. SHINYA Y, Herndon JS, Palit SR, Hong S, et al
    Impact of the extent of tumor resection on adrenal function recovery after transsphenoidal surgery for nonfunctioning pituitary adenomas.
    J Neurosurg. 2025 Nov 7:1-9. doi: 10.3171/2025.6.JNS25607.
    PubMed         Abstract available
    
    

    
    Nat Rev Neurol

42. DE LUCAS SANZ M, Niclou SP, Golebiewska A
    Modelling brain tumours with organoids: towards precision medicine in neuro-oncology.
    Nat Rev Neurol. 2026 Mar 10. doi: 10.1038/s41582-026-01190.
    PubMed         Abstract available
    
    

    
    Neuro Oncol

43. OMURO A, DeAngelis LM, Polley MC, Correa D, et al
    Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma.
    Neuro Oncol. 2026;28:371-382.
    PubMed         Abstract available
    
    
44. DE LA FUENTE MI, Brastianos PK, Gampel B, Nassiri F, et al
    Reflecting on scientific growth and innovation as the Society for Neuro-Oncology turns 30.
    Neuro Oncol. 2026;28:7-18.
    PubMed         Abstract available
    
    
45. HACK K, Jauch-Speer SL, Kresbach C, Schoof M, et al
    Single-nucleus transcriptomics of spinal ependymoma subtypes recognizes intratumoral heterogeneity.
    Neuro Oncol. 2026;28:86-98.
    PubMed         Abstract available
    
    
46. GROSSMAN SA, Barone A, Strowd RE, Rais R, et al
    Evaluating "Brain Permeability": A Critical Issue for the Development of Therapeutic Agents for Primary and Metastatic Brain Tumors.
    Neuro Oncol. 2026 Mar 12:noag051. doi: 10.1093.
    PubMed         Abstract available
    
    
47. ILIE MD, Flores-Martinez A, Chanal M, Lepetit M, et al
    Mast cells act as pro-angiogenic and pro-tumorigenic players in pituitary gonadotroph tumors.
    Neuro Oncol. 2026;28:175-190.
    PubMed         Abstract available
    
    
48. SHARMA A, Kennedy LB, Van Swearingen AED, Ahluwalia MS, et al
    Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative.
    Neuro Oncol. 2026;28:319-333.
    PubMed         Abstract available
    
    
49. VON HOFF K, Obrecht-Sturm D, Ghasemi DR, Wenning J, et al
    Developing an advanced risk stratification model for pediatric intracranial ependymoma based on the prospective trial E-HIT2000 and subsequent registries.
    Neuro Oncol. 2026;28:520-534.
    PubMed         Abstract available
    
    
50. RHEE JY, Tentor Z, Sounack T, Durieux B, et al
    Scalable tracking of symptoms in the electronic health record using large language models in patients with central nervous system cancers undergoing therapy.
    Neuro Oncol. 2026;28:206-217.
    PubMed         Abstract available
    
    
51. TZARIDIS T, Liu J, Chien FL, Malhotra A, et al
    ONC206 demonstrates potent anti-tumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma.
    Neuro Oncol. 2026 Mar 12:noag053. doi: 10.1093.
    PubMed         Abstract available
    
    
52. JIANG Z, Xie L, Zhou H, Geng Y, et al
    Transcriptomics-guided high-throughput drug screening identifies potent therapies for P53 pathway altered DIPG/DMG.
    Neuro Oncol. 2026;28:251-267.
    PubMed         Abstract available
    
    

    
    Neuroradiology

53. WANG X, Li W, Guo Y, Kang Y, et al
    Differentiating medulloblastoma and pilocytic astrocytoma in children based on multimodal MRI radiomics model.
    Neuroradiology. 2026 Mar 7. doi: 10.1007/s00234-026-03925.
    PubMed         Abstract available
    
    

    
    Neurosurgery

54. WEBER F, Vychopen M, Kurt GZ, Pfahl A, et al
    In Vivo Hyperspectral Imaging of Vasogenic Edema and Cortical Oxygenation in Meningiomas: A Subgroup Interim Analysis of a Prospective Study.
    Neurosurgery. 2026 Mar 13. doi: 10.1227/neu.0000000000003991.
    PubMed         Abstract available
    
    

    
    Pediatr Neurosurg

55. SHENTU Y, Bhayana K, Bonfante-Mejia EE, Fraser SM, et al
    Internal Cerebral Vein Thrombus Mimicking Thalamic Neoplasm in a Child with Down Syndrome.
    Pediatr Neurosurg. 2025;60:114-119.
    PubMed         Abstract available
    
    
56. YINDEEDEJ V, Mungmee A, Lokhoonsombut T, Konmun S, et al
    Combined Transtemporal and High Parietal Approach for Large Trigonal Intraventricular Tumor: A Case Report.
    Pediatr Neurosurg. 2025;60:120-126.
    PubMed         Abstract available
    
    

    
    PLoS Biol

57. WU S, Cao R, Huang X, Feng Q, et al
    USP7 facilitates brain tumor survival upon glucose deprivation by regulating phosphofructokinase muscle-type nuclear translocation in mice.
    PLoS Biol. 2026;24:e3003698.
    PubMed         Abstract available
    
    

    
    PLoS One

58. BAO H, Liu K, Gao N, Su Y, et al
    NFIC suppressed the development of Glioma via modulating the balance of SHP2/PI3K and NF-kappaB/PTEN Signaling.
    PLoS One. 2026;21:e0341816.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

59. WAIRIRI L
    FET PET Does Not Improve Outcomes Compared with MRI for Re-Irradiation of Recurrent Glioblastoma: GLIAA/NOA-10 ARO2013-01 Trial.
    Radiol Imaging Cancer. 2026;8:e269004.
    PubMed        
    
    
60. SINGH A, Qureshy FA, Kurtz A, Bhattacharya M, et al
    Digital Twins in Neuro-Oncology: A Systematic Review of Current Implementations, Technical Strategies, and Clinical Applications.
    Radiol Imaging Cancer. 2026;8:e250567.
    PubMed         Abstract available
    
    

    
    Radiologia (Engl Ed)

61. LOPEZ-RUEDA A, Pons A, Majos C, Chirife O, et al
    Eligibility assessment for yttrium-90 radioembolisation in patients with recurrent glioblastoma: A single-centre cohort study based on the FRONTIER clinical trial criteria (NCT05303467).
    Radiologia (Engl Ed). 2026;68:501691.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum